Paysign Q4 2024 Earnings Report
Key Takeaways
Paysign's Q4 2024 performance featured double-digit revenue growth driven by significant expansion in the patient affordability segment, while plasma revenue softened due to market normalization. The company posted $1.37 million in net income and ended the quarter with $10.77 million in cash.
Total Q4 2024 revenue was $15.61 million, up 14% year-over-year.
Net income for the quarter reached $1.37 million with diluted EPS of $0.02.
Patient affordability revenue surged by 156.5% to $4.31 million.
Plasma revenue declined 6.2% to $10.80 million due to normalized inventory levels.
Paysign
Paysign
Paysign Revenue by Segment
Forward Guidance
Paysign anticipates continued growth in 2025, driven by patient affordability revenue, while plasma revenue is expected to moderate. Full-year revenue is projected between $68.5 million and $70.0 million, with pharma revenue doubling year-over-year.
Positive Outlook
- Pharma revenue expected to grow at least 100% in 2025.
- Plasma revenue to make up approximately 57.5% of total revenue.
- Continued strength in patient affordability business with increasing contribution to revenue.
- Anticipated full-year gross profit margins of 62%-64%.
- Expected adjusted EBITDA in the range of $12.5 to $13.5 million for full-year 2025.
Challenges Ahead
- Near-term slowdown in plasma business due to industry oversupply.
- Plasma revenue expected to decline year-over-year in early 2025.
- Operating expenses projected to increase due to acquisitions and hiring.
- Revenue to be higher in the first half of 2025 than the second half, impacting income seasonally.
- Depreciation and amortization expenses expected between $10.5 million and $11.5 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income